The TGA has banned a safe and effective COVID-19 treatment. One that could end the pandemic and save lives today.

Why?

A treatment that’s safer than paracetamol*

Australian scientists discovered it killed SARS-COV-2 stone cold in 48 hours.

It has an unparalleled safety profile with 3.7 billion doses administered in humans over 35+ years and it’s won a Nobel Prize for treating infections.

It’s called ivermectin. The problem?

It’s banned for use in the treatment and prevention of COVID-19

Why has ivermectin been banned?

  • It’s off-patent & very cheap which means extremely small profit for pharmaceutical companies.
  • Newly patented COVID drugs/vaccines have made and will continue to make billions of dollars.
  • Emergency use of new COVID medicines can only be granted when no alternatives are available.

Take action today and help these medical professional campaign against the TGA

Take Action Now

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on reddit
Reddit
Share on telegram
Telegram
Share on whatsapp
WhatsApp
Share on email
Email

Related Stories

Business Spotlight

RDA Business Directory Spotlight

Melbourne Decking & Landscaping RDA Business Directory Spotlight– Melbourne Decking & Landscaping | https://www.reignitedemocracyaustralia.com.au/places/melbourne-decking-and-landscaping/ RDA now has 499+ listings on our Business Directory, an easy

Read More »
Latest News

Support Reclaim the Line

Support Reclaim the Line | ttps://consciousclothing.shop/products/reclaimtheline-free-the-nation-t-shirt-mens-womens-white Reclaim The Line is gearing up for major events all across the country again this weekend. If you’re looking

Read More »

Responses

  1. Worth a read ….
    Risk Assessment and Risk Management Plan
    for
    DIR 180
    Commercial supply of a genetically modified
    COVID-19 vaccine
    Applicant: AstraZeneca Pty Ltd
    February 2021
    https://www.ogtr.gov.au/sites/default/files/2021-06/dir180-full_risk_assessment_and_risk_management_plan.pdf

    “Previous clinical trials Phase 1/2 clinical trial with the GM vaccine ChAdOx1-S [recombinant] (also
    known as AZD1222, ChAdOx1 nCoV-19) was conducted and completed in the
    United Kingdom (UK) to test the safety of the vaccine in adults aged 18-55
    years.
    Current approvals • Clinical trials with the GM vaccine ChAdOx1-S [recombinant] (also known as
    AZD1222, ChAdOx1 nCoV-19) are approved and are currently ongoing in
    several overseas jurisdictions including the UK, the United States (US),

    1 The title of the licence application submitted by AstraZeneca is “Commercial release of a COVID-19 vaccine
    AstraZeneca to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)”.
    DIR 180 – Risk Assessment and Risk Management Plan (February 2021) Office of the Gene Technology Regulator
    Summary II
    Brazil, South Africa, Argentina, Chile, Colombia, Japan, Peru and the
    Russian Federation.
    • The GM vaccine may be manufactured in Australia under a licence for
    Dealings Not involving Intentional Release (DNIR) of a GMO into the
    environment (DNIR-630 and DNIR-632) or imported under a Notifiable Low
    Risk Dealing authorisation.
    • The GM vaccine is currently approved for emergency use in several
    countries including the UK, Argentina, Brazil, El Salvador, India, Dominican
    Republic, Mexico, Morocco and Pakistan.
    • The GM vaccine has been approved for commercial use in the European
    Union.
    Proposed locations Australia-wide
    Primary purpose Commercial supply of the GM COVID-19 vaccine”